Uncategorized Archives - Page 2 of 15

MondayNov 20, 2023 2:30 pm

QualityStocksNewsBreaks – Safety Shot Inc. (NASDAQ: SHOT) Set for Dec. 7 California Launch

Safety Shot (NASDAQ: SHOT) today announced the west coast launch of Safety Shot, the first patented beverage on Earth that helps people feel better faster by reducing blood alcohol content and boosting clarity. Safety Shot is a nutraceutical functional beverage, created by industry experts and validated by research, that accelerates the body’s break-down of alcohol while aiding in recovery and rehydration. “Our west coast launch in the Los Angeles area is aligned with our national online direct-to-consumer sales launch through our own website and through Amazon. We are super excited to have people try Safety Shot. We have given out…

ThursdayNov 16, 2023 3:03 pm

QualityStocksNewsBreaks – FuelPositive Corporation (TSX.V: NHHH) (OTCQB: NHHHF) Partners with Cipher Neutron to Offer Green-Energy Solution

FuelPositive (TSX.V: NHHH) (OTCQB: NHHHF), a Canadian-based, growth-stage company committed to providing commercially viable and sustainable, cradle-to-cradle, clean-energy solutions, has placed its initial purchase order with Cipher Neutron Inc. (“CN”) for its unique Anion Exchange Membrane (“AEM”) Electrolyser Technology. According to the announcement, CN’s Green Hydrogen AEM Electrolysers combined with its reversible fuel cell technology can produce hydrogen without using any platinum group metals, including platinum, iridium and ruthenium. FuelPositive is using CN AEM Green Hydrogen Electrolyser Technology because its one of the most innovative, affordable and sustainable green-hydrogen solutions available for producing high-volume, high-pressure green hydrogen. The companies noted that,…

TuesdayNov 14, 2023 1:00 pm

QualityStocksNewsBreaks – SuperCom Ltd. (NASDAQ: SPCB) Announces Strong Q3 2023 Results Including 550% YoY EBITDA Growth and 5-Year-Record Net Profit

SuperCom Ltd. (NASDAQ: SPCB), a global provider of secured solutions for the e-Government, IoT and cybersecurity sectors, today announced financial and operating results for the three and nine months ended Sept. 30, 2023. “We are excited to announce exceptional operational performance for Q3 2023, which is reflected in our financial results. A 5-year record net profit, remarkable 550% growth in EBITDA and 74% growth in gross profit margins are clear indicators of the successful execution of our growth strategy. The significant increase in the company’s profit margins is driven by the forward momentum we’ve maintained across our projects, where margins…

FridayNov 03, 2023 12:35 pm

QualityStocksNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Announces Plans to Release Q3 2023 Financial Report, Host Corporate Update Call

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, has announced plans to report its financial results for Q3 2023. The company will release the results on Nov. 10, 2023, before the market opens. In addition, the company announced plans to host a conference call and webcast that same day. During the call, key company leaders will discuss the Q3 financial report as well as provide an update on its clinical programs and corporate activities; the call will also include time for a Q&A. To access the call, individuals should dial 1-877-407-0789 (domestic)…

MondayOct 16, 2023 11:20 am

QualityStocksNewsBreaks — Longeveron Inc. (NASDAQ: LGVN; LGVNR) Closes on $4M Registered Direct Offering

Longeveron (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (“HLHS”), Alzheimer’s disease and Aging-Related Frailty, closed on its previously announced registered direct offering. The offering was comprised of 2,424,243 shares of Class A common stock or common stock equivalents priced at $1.65 per share, or common stock equivalent. In addition, Longeveron issued unregistered Series A warrants in a concurrent private placement; the private placement included 2,424,243 shares of LGVN common stock and unregistered Series B warrants. The warrants, which have an exercise price of $1.65 per share, are…

ThursdayAug 17, 2023 1:11 pm

QualityStocksNewsBreaks — Reflex Advanced Materials Corp. (CSE: RFLX) (OTCQB: RFLXF) (FSE: HF2) Issues 100K Shares to Fulfill Mineral Property Option Agreement

Reflex Advanced Materials (CSE: RFLX) (OTCQB: RFLXF) (FSE: HF2), a mineral exploration company, has issued 100,000 common shares to fulfill its obligations to date outlined in a mineral property option agreement. According to the announcement, the issue of shares is in connection with the Sept. 1, 2021, agreement, which is between the company and Alex Pleson and which gives Reflex Advanced Materials the sole and exclusive right to acquire up to a 100% interest in the Zigzag lithium property. The ZigZag lithium property includes eight mining claims comprising an estimated 2,710 hectares near Crescent Lake, Ontario, a region known for…

MondayAug 07, 2023 2:35 pm

QualityStocksNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) to Host 2Q Conference Call and Webcast

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, has announced plans to hold its Second Quarter Town Hall Update to share current events and 2023 financial highlights following the filing of its 10-Q update with the U.S. Securities and Exchange Commission. The company’s CEO and Chairman William Santana Li will deliver a pre-recorded video update at the top of the meeting to cover Q2 2023 performance metrics followed by a live question-and-answer session with supporters, investors and analysts in an intimate online forum with no moderator. The announcement reads, “The conference…

ThursdayJul 20, 2023 1:10 pm

QualityStocksNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces Results from ‘Groundbreaking’ Sponsored Study Measuring Psychedelic Effects

Cybin (NEO: CYBN) (NYSE American: CYBN), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, is reporting on the release of study findings. Cybin sponsored the study, which was conducted by Kernel, a leader in noninvasive neuroimaging. Titled “Measuring acute effects of subanesthetic ketamine on cerebrovascular hemodynamics in humans using TD-fNIRS,” the study was published in “Scientific Reports from the Nature Portfolio of Journals” and evaluated the ability of Kernel’s Flow1 system to capture and analyze brain changes resulting from the administration of a psychoactive substance. According to the announcement, the single-blind, placebo-controlled…

ThursdayJul 06, 2023 2:02 pm

QualityStocksNewsBreaks – Knightscope, Inc. (NASDAQ: KSCP) Adds to List of Growing Sales; Receives Two New Orders

Knightscope (NASDAQ: KSCP), a leading developer of autonomous security robots (“ASRs”) and blue light emergency communication systems, continues to see added sales and is building on its 2023 revenue. The company has received an order for an ASR and an order for two K1 Call Boxes. According to the announcement, the ASR order came from one of the largest churches in the nation; the church has more than 35,000 people who attend congregations on 17 campuses. The church anticipates having Knightscope’s ASR patrol the parking lot of one its largest campus, a 105-acre site that includes an auditorium which seats…

WednesdayJun 21, 2023 2:19 pm

QualityStocksNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Secures US Patent for SPU-21 Treatment for Autoimmune Disease

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued U.S. Patent 16/825,371 titled “Peptide-Targeted Liposomal Delivery for Treatment, Diagnosis and Imaging of Diseases and Disorders.” According to the announcement, the new patent claims cover the company’s portfolio drug SPU-21, a peptide-guided anti-arthritis drug, as a method of selectively targeting inflamed synovial tissue. “Our SPU-21 liposomal homing peptides, licensed from the University of Maryland, Baltimore, are able to identify markers of arthritic inflammation in joints and have potential for the development…

Site Search

Company Search

Category: Uncategorized